Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts

Immunological Reviews

Volumn 157, Issue , 1997, Pages 195-216

  O'Reilly, Richard J ^a   Small, Trudy N ^a   Papadopoulos, Esperanza ^a   Lucas, Kenneth ^a   Lacerda, Joao ^a   Koulova, Lydia ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CELL NUCLEUS ANTIGEN; EPITOPE; INTERLEUKIN 2; MEMBRANE PROTEIN; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELLULAR IMMUNITY; CLINICAL TRIAL; EPITHELIUM CELL; EPSTEIN BARR VIRUS; GENOTYPE; HLA MATCHING; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LATENT VIRUS INFECTION; LYMPHOCYTE TRANSFORMATION; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND; T LYMPHOCYTE;

BONE MARROW TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOPROLIFERATIVE DISORDERS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030873733     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00983.x     Document Type: Review

References (186)

1. Miller G. Epstein-Barr virus: biology, pathogenesis and medical aspects. In: Fields BN, Knipe DM, eds. Virology. New York: Raven Press; 1990. p. 1921-1958.
2. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 1968;59:94-101.
3. Miller G, Niederman JC, Andrews LL. Prolonged oropharyngeal excretion of Epstein-Barr virus after infectious mononucleosis. N Engl J Med 1973;288:229-232.
4. Golden HD, et al. Leukocyte transforming agent prolonged excretion by patients with mononucleosis and excretion by normal individuals. J Infect Dis 1973;127:471-473.
5. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985;35:35-42.
6. Tosato G, et al. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest 1984;73:1789-1795.
7. Tosato G. The Epstein-Barr virus and the immune system. Adv Cancer Res 1987;49:75-125.
8. Rickinson AB, et al. Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res 1981;41:4216-4221.
9. Svedmyr E, Jondal M. Cytotoxic effector cells specific for B cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci USA 1975;72:1622-1666.
10. Moss DJ, Rickinson AB, Pope JH. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 1987;22:662-668.
11. Bourgeault I, et al. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T-Lymphocytes. Clin Exp Immunol 1991;84:501-507.
12. Kusunoki Y, et al. A positive correlation between the precursor frequency of cytotoxic lymphocytes to autologous Epstein-Barr virus-transformed B cells and antibody titer level against Epstein-Barr virus-associated nuclear antigen in healthy seropositive individuals. Microbiol Immunol 1993;37:461-469.
13. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RG. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996;87:2594-2603.
14. Shapiro RS, et al. Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234-1243.
15. Purtilo DT, et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's Disease). Lancet 1975;1:935-940.
16. Penn I. Neoplastic consequences of transplantation and chemotherapy. Cancer Detect Prev 1987;1 (Suppl 1): 149-157.
17. Kaplan LD, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989;261:719-724.
18. Ziegler JL, et al. Non-Hodgkin's lymphoma in 90 homosexual men. New Engl J Med 1984;311:565-570.
19. Klein E, Klein G, Levine PH. Immunological control of human lymphoma: discussion. Cancer Res 1981;41:4210-4215.
20. Papadopoulos EB, et al. Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorders complicating allogeneic marrow transplantation. New Engl J Med 1994;330:1185-1191.
21. Heslop HE, Brenner MK, Rooney CM. Donor T-cells to treat EBV-associated lymphoma. N Engl J Med 1994;331:679-680.
22. Rooney CM, et al. Use of gene-modified virus-specific T-Lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
23. Servida P, et al. Gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in a patient affected by EBV-induced lymphoma. Blood 1993;82:214 (Abstract).
24. Kieff E, Liebowitz D. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Channock RM, et al. eds. Virology. 2nd ed. New York: Raven Press; 1990. p. 1889-1920.
25. Rogers RP, Strominger JL, Speck SH. Epstein-Barr virus B-lymphocytes: viral gene expression and function in latency. Adv Cancer Res 1992;58:1-26.
26. Dillner J, Kallin B. The Epstein-Barr virus proteins. Adv Cancer Res 1988;50:95-158.
27. Cooper NR, Moore MD, Nemerow GR. Immunobiology of CR2, the B lymphocyte receptor for EBV and C3D complement fragment. Annu Rev Immunol 1988;6:85-113.
28. Cheung RK, Dosch HM. The Tyrosine Kinase lck is critically involved in the growth transformation of human B-lymphocytes. J Biol Chem 1991;266:8667-8670.
29. 4P. Virology 1993;193:700-708.
30. Miyazaki I, Cheung RK, Dosch HM. Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein-Barr virus. J Exp Med 1993;178:439-447.
31. Pritchett R, Pendersen M, Kieff E. Complexities of EBV homologous in continuous lymphoblastoid cell lines. Virology 1976;74:227-231.
32. Hayward S, Kieff E. DNA of Epstem virus. II. Comparison of the monoclonal weights of restriction endonuclease fragments of the DNA of Epstein-Barr virus strains and identification of end fragments of the B95-8 strain. J Virol 1977;23:421-429.
33. Sixbey JW, et al. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984;310:1225-1230.
34. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985;313:812-815.
35. Rawlins DR, et al. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985;42:859-868.
36. Gahn TA, Schildkraut CL. The Epstein-Barr virus origin of plasmic replication, oriP contains both the initiation and termination sites of DNA replication. Cell 1989;58:527-535.
37. Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 1989;63:2644-2649.
38. Jeang KT, Hayward SD. Organization of the Epstein-Barr virus DNA molecule. III. Location of the P3HR-1 deletion junction and characterization of the NotI repeat units that form part of the template for an abundant 12-O-tetradecanoylphorbol-13-acetate-induced mRNA transcript. J Virol 1983;48:135-148.
39. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B-lymphocytes. Nature 1989;340:393-397.
40. Cohen JI, et al. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Prot Natl Acad Sci USA 1989;86:9558-9562.
41. Henkel T, Ling PD, Hayward SD, Peterson MG. Mediation of Epstein-Barr virus EBNA-2 transactivation by recombination signal-binding protein Jk. Science 1994;262:92-95.
42. Jarriault S, Brou C, Logeat F, Schroeter E, Kopan R, Israel A. Signalling downstream of activated notch. Nature 1995;377:355-358.
43. Wang F, Gregory CD, Rowe M. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci USA 1987;84:3452-3456.
44. Cordier M, et al. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol 1990;64:1002-1013.
45. Mannick JB, et al. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 1991;65:6826-6837.
46. Tomkinson B, Kieff E. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation. J Virol 1992;66:2893-2903.
47. Robertson ES, Lin J, Kieff, E. The ammo-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJκ: J Virol 1996;70:3068-3074.
48. Silins SL, Sculley TB. Burkitt's lymphoma cells are resistant to programmed cell death in the presence of the Epstein-Barr virus latent antigen DBNA-4. Int J Cancer 1995;60:65-72.
49. Szekely L, et al. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, hinds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 1993;90:5455-5459.
50. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993;90:9150-9154.
51. Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 1996;88:242-251.
52. Henderson S, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-1115.
53. Mosialos G, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-399.
54. Wang D, et al. Epstein-Barr virus latent infection membrane protein (LMP) alters human B lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988;62:4173-4184.
55. Wang F, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B-lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990;64:2309-2318.
56. Jurgen W, Schirrmacher V, Mosier D. Induction of CD44 expression by the Epstein-Barr-virus latent membrane protein LMP1 is associated with lymphoma dissemination. Int J Cancer 1995;61:363-369.
57. Miller G. The switch between latency and replication of Epstein-Barr virus. J Infect Dis 1990;161:833-844.
58. Zhang Q, Gursch D, Kenney S. Functional and physical interaction between p53 and ZALF1: implications for Epstein-Barr virus latency. Mol Cell Biol 1994;14:1929-1938.
59. Pearson GR, et al. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 1987;160:151-161.
60. Henderson S, et al. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 1993;90:8479-8483.
61. Murray PG, et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in post-transplantation lymphoproliferative disorders. Blood 1996;87:706-711.
62. Masood R, et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 1995;85:3423-3430.
63. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 1992;80:1289-1298.
64. Durandy A, et al. Role of Il-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice. J Immunol 1994;152:5361-5367.
65. Emilie D, et al. Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood 1992;80:498-504.
66. Nadal D, Albini B, Schlapter E, Bernstein JM, Ogra PL. Role of Epstein-Barr virus and interleukin 6 in the development of lymphomas of human origin in SCID mice engrafted with human tonsillar mononuclear cells. J Gen Virol 1992;73:113-121.
67. Viera P, et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991;88:1172-1176.
68. Baiocchi RA, et al. Lymphogenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 1995;85:1063-1074.
69. Taga K, Tosato G. Il-10 inhibits mitogen-induced T-cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992;148:1143-1148.
70. Ralph PI, et al. IL-10 T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992;148:808-814.
71. Florentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-1095.
72. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT. Viral interluekin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 1995;182:477-486.
73. Scala G, et al. Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med 1990;172:61-68.
74. Tanner J, Tosato G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 1991;88:239-247
75. Henle W, Henle GE, Horwitz CA. Epstein-Barr virus specific diagnostic lests in infectious mononucleosis. Hum Pathol 1974;5:551-565.
76. Seeley J, et al. Epstein-Barr virus selective T-cells in infectious mononucleosis are not restricted to HLA-A and B antigens. J Immunol 1981;81:1271-1293.
77. Masucci MG, et al. Large granular lymphocytosis inhibit the growth of autologous Epstein-Barr virus-infected B cells. Cell Immunol 1981;127:293-300.
78. Svedmyr E, Jondal M. Cytotoxic effector cells specific for B cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci USA 1975;72:1622-1626.
79. Tanaka Y, Sugamura K, Hinuma Y. Heterogeneity of allogeneic restriction of human cytotoxic T-cell clones specific for Epstein-Barr virus. J Immunol 1982;128:1241-1245.
80. Chen BP, et al. Restriction of Epstein-Barr virus-specific cytotoxic T-cells by HLA-A,-B and -C molecules. Hum Immunol 1989;26:137-147.
81. Tomkinson BE, Maziarz R, Sullivan JL. Characterization of the T-cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol 1989;143:660-670.
82. Cesano A, Visonneau S, Cioe L, Clark SC, Rovera G, Santoli D. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J Clin Invest 1994;94:1076-1084.
83. Sehendel DJ, et al. Cytotoxic T-Lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides. J Immunol 1992;149:2406-2414.
84. Burrows SR, et al. An alloresponse in humans is dominated by cytotoxic T-Lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-vs-host disease. J Exp Med 1994;179:1155-1161.
85. Haynes BF, et al. Emergence of suppressor cells of immunoglobulin synthesis during acute Epstein-Barr virus-induced infectious mononucleosis. J Immunol 1979;123:2095-2101.
86. Tosato G, et al. Activation of suppressor T-cells during Epstein-Barr virus-induced infectious mononucleosis. N Engl J Med 1979;301:1133-1137.
87. Tosato G, Blaese RM. Epstein-Barr virus infection and immunoregulation in man. Adv Immunol 1985;37:99-149.
88. Wang F, et al. Suppressor T-cell clones from patients with acute Epstein-Barr virus-induced infectious mononucleosis. J Clin Invest 1987;79:7-14.
89. Thorley-Lawson DA, Chess L, Strominger JL. Suppression of Epstein-Barr virus infection. A new role for the adult human T lymphocyte. J Exp Med 1977;146:494-508.
90. Moss DJ, Rickinson AB, Pope JH. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 1978;22:662-668.
91. Rickinson AB, Moss DJ, Pope JH. Long-term T-cell immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus infected leukocyte cultures. Int J Cancer 1979;23:610-617.
92. Misko IS, Moss DJ, Pope JH. HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci USA 1980;77:4247-4250.
93. Rickinson AB, Wallace LE, Epstein MA. HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells. Nature 1980;283:865-867.
94. Wallace LE, et al. Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 1982;297:413-415.
95. Meuer SC, et al. Human cytotoxic T-cell clones directed at autologous virus-transformed targets: further evidence for linkage of genetic restriction to T4 and T8 surface glycoproteins. J Immunol 1983;131:186-190.
96. Misko IS, et al. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer 1984;33:239-243.
97. + cell elimination regularly develops in uncloned human antiviral cell lines. J Immunol 1989;142:252-256.
98. Kaminski E, et al. Prediction of graft versus host disease by frequency analysis of cytotoxic T-cells after unrelated donor bone marrow transplantation. Transplantation 1989;48:608-613.
99. Tosato G, Yarchoan R, Blaese RM. Relationship between immunoglobulin production and immortalization by Epstein-Barr virus. J Immunol 1985;135:959-964.
100. Rocchi GA, et al. Quantitative evaluation of Epstein-Barr virus infected mononuclear peripheral blood leukocytes in infectious mononucleosis. N Engl J Med 1977;296:132-134.
101. Tosato G, et al. Characteristic T-cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). J Immunol 1985;134:3082-3088.
102. Rowe M, et al. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991;173:147-158.
103. Picchio GR, et al. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res 1992;52:2468-2477.
104. Murray RJ, et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992;176:157-168.
105. Khana R, et al. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992;176:169-176.
106. Rickinson AG, Lee SP, Steven NM. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1997;8:492-497.
107. Tamaki H, Beaulieu BL, Somasundaran M, Sullivan JL. Major histocompatibility complex class I-restricted cytotoxic T-lymphocyte responses to Epstein-Barr virus in children. J Infect Dis 1995;172:739-746.
108. Wrightham MN, et al. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology 1995;208:521-530.
109. Stuber G, et al. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay: low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int Immunol 1995;7:653-669.
110. Levitskaya J, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-688.
111. Khanna R, Burrows SR, Steigerwald-Mullen PM, Thomson SA, Kurilla MG, Moss DJ. Isolation of cytotoxic T-lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 1995;214:633-637.
112. Lee SP, et al. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T-lymphocyte epitope are prevalent in a highly B35.01-positive African population. Eur J Immunol 1995;25:102-110.
113. Lee SP, Thomas WA, Blake NW, Rickinson AB. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Eur J Immunol 1996;26:1875-1883
114. Gaviolo R, et al. Multiple HLA A11-restricted cytotoxic T lymphocyte epiptopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 1993;67:1572-1578.
115. Steven NM, Leese AM, Annels NE, Lee SP. Epitope focusing in the primary cytotoxic T-cell response to Epstein-Barr Virus and its relationship to T-cell memory. J Exp Med 1996;184:1802-1813.
116. Levitsky V, Zhang Q-J, Levitskaya J, Maaucci MG. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen-1. J Exp Med 1996;183:915-926.
117. + population. Science 1993;260:98-100.
118. Gavioli R, et al. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11 restricted cytotoxic T-Lymphocytes: implications for down-regulation of HLA-A11 in Burkitt's lymphoma. ProcNatl Acad Sci USA 1992;89:5862-5866
119. Lee SP. et al. HLA A2.I-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 1993;67:7428-7435.
120. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. J Exp Med 1993;178:879-887.
121. Heslop HE, et al. Long-term restoration of immunity against Epsiein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
122. + virus-specific cytotoxic T-cells which recognize Epstein-Barr virus lytic antigen BHRF1. Virology 1996;219:489-492.
123. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott-Raven; 1996. p. 2397-2446
124. Levine AM. Non-Hodgkin's lymphomas and other malignancies in the acquired immune deficiency syndrome. Semin Oncol 1987;14:34-39
125. Serraino D, et al. The epidemiology of AIDS-associated non-Hodgkin's lymphoma in the World Health Organization European Region. Br J Cancer 1992;66:912-916.
126. Andiman WA, et al. Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS. Lancet 1985;ii:1390-1393.
127. Shibata D, Weiss LM, Nathwani BN, Brynes RK, Levine AM. Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma. Blood 1991;77:1527-1533.
128. Penn I. Allograft transplant cancer registry. In: Purtilo DT, ed. Immune deficiency and cancer: Epstein-Barr virus and lymphoproliferative malignancies. New York: Plenum Publishing Corp; 1984. p. 281.
129. Weintraub J, Warlike RA. Lymphoma in cardiac allograft recipients. Clinical and histological features and immunological phenotype. Transplantation 1982;33:347-351.
130. Randhawa PS, et al. The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients. Am J Clin Pathol 1989;92:177-185.
131. Hanto DW, et al. Epstein-Barr virus, immunodeficiency and B-cell lymphoproliferation. Transplantation 1985;39:461-472.
132. Opelz G, Henderson R. Incidence of non-Hodgkin's lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-1516.
133. Canfield CW, et al. Fulminant Epstein-Barr virus-associated post-transplant lymphoproliferative disorders following OKT3 therapy. Clin Transplant 1992;6:1-9
134. Murray BM, et al. Fatal lymphoma in association with OKT3 antibody therapy diagnosed by allograft biopsy. Clin Transplant 1992;6:35-38.
135. Swinnen LJ, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323:1723-1728.
136. Lucas K, et al. The development of Epstein-Barr virus specific cellular immunity following allogeneic marrow transplantation. Blood 1994;84:98 (Abstract).
137. Zutter MM, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1984;72:520-570.
138. Martin PJ, et al. Fatal Epstein-Barr virus-associated proliferation of donor B-cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med 1984;101:310-315.
139. Skinner JC, et al. B cell lymphoproliferative disorders following T-cell depleted allogeneic hone marrow transplantation. Am J Ped Hemat/Onc 1988;10:112-119.
140. Antin JH, et al. Selective depletion of bone marrow T-lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991;78:2139-2149.
141. O'Reilly RJ, Lacerda JF, Lucas KG, Rosenfield NS, Small TM, Papadopoulos HB. Adoptive cell therapy with donor lymphocytes for EBV associated lymphomas developing after allogeneic marrow transplants. In: Devita V, Hellman S, Rosenberg S, eds. Important Advances in Oncology 1996. Philadelphia/ New York: 1996. p. 149-166.
142. Hale G, Cobbold S, Waldmann H. T-cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation 1988;45:753-759.
143. Aversa F, et al. Successful engraftment of T-cell depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-3955.
144. Bonnefoy-Berard N, Flacher M, Revillard JP. Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. Blood 1992;79:2164-2170.
145. Casper J, et al. Unrelated bone marrow transplants for children with leukemia or myelodysplasia. Blood 1995;85:2354-2363.
146. Nalesnik MA, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine-A prednisone immunosuppression. Am J Pathol 1988;133:173-192.
147. Thomas JA, Allday MJ, Crawford DH. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res 1991;57:329-380.
148. Knowles DM, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552-565.
149. Papadopoulos EB, et al. Current results of donor leukocyte infusions (DLI) for treatment of Epstein-Barr virus associated lymphoproliferative disorders (FBV LPD) following related and unrelated T-cell depleted bone marrow transplant (TCD BMT). Blood 1996;88:681 (Abstract).
150. Young L, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321:1080-1085.
151. Kernan NA, et al. Clonable T-Lymphocytes in T-cell-depleted bone marrow transplants correlate with development of graft vs. host disease. Blood 1986;68:770-773.
152. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Joy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immun Defic Syndr 1991;4: 770-776.
153. + T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. Arch Intern Med 1995;155:1537-1542.
154. Small TN, et al. Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant J 1997;2(3) (In press).
155. Small TN, Flomenberg N, Black P, O'Reilly RJ, Kernan NA. Comparison of immune reconstitution following T-cell depleted bone marrow transplantation from related versus unrelated donors. Blood 1996;78:226 (Abstract).
156. Santamaria P, et al. Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs. Blood 1994;83:280-287.
157. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994;83:2715-2722.
158. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-984.
159. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated posttransplantation lymphoproliferative disease. Br J Haematol 1995;89:98-103.
160. Walker RC, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995;20:1346-1353.
161. Ho M, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988;45:719-727.
162. Frank D, et al. Post-transplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 1995;85:1396-1403.
163. Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA-2 on the growth phenotype of virus-transformed B cells. J Virol 1987;61:1310-1317.
164. Klein C, et al. EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. Br J Haematol 1995;91:938-940.
165. Hu L, et al. Clonability and tumorigenicity of human epithelial cells expressing the EBV-encoded membrane protein LMP1. Oncogene 1993;8:1575-1583.
166. Heslop HE, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
167. Bonini C, et al. A pilot study of HSV-TK gene transfer into donor peripheral blood lymphocytes for controlled BVL after allo-BMT. Blood 1996;88 (Suppl 1):487 (Abstract).
168. Kuzushima K, et al. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 1996;103:192-198.
169. Mackinnon S, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia following bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-1268.
170. Riddell SR, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 1992;257:238-241.
171. Walter EA, et al. Reconstitution of cellular immunity against CMV in recipients of allogeneic bone marrow by adoptive transfer of T-cell clones from the donor. M Engl J Med 1995;334:601.
172. Heslop HE, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
173. Yang SY, Milford E, Hammerling U, Dupont B. Description of the reference panel of B-lymphoblastoid cell lines for factors of the HLA system: the B-cell line panel designed for the tenth international histocompatibility workshop (1987). In: Dupont B, ed. Immunobiology of HLA. New York: Springer Verlag; 1989. p. 11-19.
174. Lacerda FJ, et al. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B-cell lymphoproliferations in xenografted C.B-17scid/scid mice. J Exp Med 1996;183:1215-1228.
175. + cytotoxic T-cells against Epstein-Barr virus-immortalized B-cell tumors in SCID mice. Transplantation 1994;58:629-633.
176. Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, Lyerly HK. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 1993;114:218-226.
177. Buchsbaum RJ, Fabry JA, Lieberman J. EBV-specific cytotoxic T lymphocytes protect against human EBV associated lymphoma in SCID mice. Immunol Lett 1996;52:145-152.
178. Lacerda JF, Ladanyi M, Jagiello C, O'Reilly RJ. Administration of rabbit anti-asialo GM1 antiserum facilitates the development of human Epstein-Barr virus-induced lymphoproliferations in xenografted C.V-17 SCID/scid mice. Transplantation 1996;61:492-497.
179. Baiocchi RA, Caligiuri MA. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in SCID/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1994;91:5577-5581.
180. Frank D, et al. Post-transplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 1995;85:1396-1403.
181. Trigg ME, et al. Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants. Cancer Treatment Reports 1985;69: 377-386.
182. Papadopoulos HB, et al. Current results of donor leukocyte infusions (DLI) for treatment of Epstein-Barr virus associated lymphoproliferative disorders (EBV LPD) following related and unrelated T-cell depleted bone marrow transplant. Blood 1996;88 (Suppl 1):681 (Abstract).
183. Sadelain M, Mulligan RC. Efficient retroviral-mediated gene transfer into murine primary lymphocytes. Eighth International Immunology Congress; 1992. (Abstract).
184. Mavilio F, et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994;83:1-12.
185. Brenner MK, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993;342:1134-1137.
186. Riddell SR, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-223.